Research Article
Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection
Table 4
Patients with vitamin D < 10 ng/mL at baseline. Objective PTH < 65 pg/mL.
| | Univariate analysis | Multivariate analysis | | Objective yes 56 (66.7) | OR (95% CI) | | OR (95% CI) | |
| VitD supplements | | | | | | Yes | 41 (66.1) | 0.91 (0.32–2.85) | 0.86 | 1.05 (0.34–3.24) | 0.92 | No | 15 (68.2) | | | | |
| TDF exposure | | | | | | Yes | 20 (52.6) | 3.24 (1.26–8.35) | 0.01 | 3.77 (1.36–10.43) | 0.01 | No | 36 (78.3) | | | | |
| NNRTI exposure | | | | | | Yes | 23 (67.3) | 1.08 (0.43–2.72) | 0.87 | 3.36 (0.55–20.50) | 0.19 | No | 33 (66) | | | | |
| PIs exposure | | | | | | Yes | 28 (59.6) | 2.11 (0.82–5.46) | 0.12 | 7.04 (1.09–45.47) | 0.04 | No | 28 (75.7) | | | | |
|
|